23 Jul Human ovary carcinoma resisting monoclonal antibody hybridoma cell line and its monoclonal antibody and application
Abstract
The present invention belongs to the field of biotechnology and cell engineering, and relates to monoclonal antibody hybridoma cell line and its construction process. Technology, the present invention features that soluble immunogen is first prepared with human ovary carcinoma tissue sample and then used to immunize BALB/c mouse, and through fusion, screening and repeated cloning in hybridoma technology, hybridoma cell line capable of secreting stably human ovary carcinoma resisting monoclonal antibody is obtained. The hybridoma cell line, named as BUPH: OVCAMab, is preserved in the preservation number of CGMCC No. 1225. The present invention also discloses the method of preparing monoclonal antibody OVCAMab with the cell line and purifying the antibody. The antibody is used in early diagnosis, intracorporeal locating, detection, metastatic focus detecting, etc. of ovary carcinoma in radioimmunoassay.
Year: 2005
Country: CN
Doc No: 1609203